Loading
Enzyme By Design is engineering a safer version of asparaginase, an enzyme medicine used against childhood acute lymphoblastic leukaemia, to remove a second activity linked to side effects. It is in laboratory testing.
Enzyme By Design uses structure-based enzyme engineering to make cancer therapeutics safer, beginning with L-asparaginases, which it engineers to remove the side activity linked to toxicity. Its stated targets are haematological cancers, with possible use in some solid tumours. The NIH RePORTER abstract describes human-like asparaginases with reduced immunogenicity, no L-glutaminase activity and long persistence. In fiscal year 2026 NCI awarded it USD 400,000 under SBIR award 1R43CA306391-01A1.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R43) 1R43CA306391-01A1: Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/